OeKolp forte

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of OeKolp forte

Property Description
Active ingredient Estriol (E3)
Form Vaginal suppositories (Pessaries)
Pharmacological class Estrogen preparation (Hormone Replacement Therapy component)
Origin Naturally occurring (Bio-identical) Estrogen
Route of Administration Vaginal (Local/Topical)

OeKolp forte is a foundational prescription-only pharmaceutical preparation used in Hormone Replacement Therapy (HRT), specifically designed for localized treatment of tissues affected by hormonal changes. It is fundamentally classified as an Estrogen preparation, belonging to the larger pharmacological group of sex hormones and modulators of the genital system. As a monotherapy, it is exclusively focused on delivering a single, specific active compound to achieve its intended therapeutic purpose, which is the replacement of deficient hormonal action.


What Type of Medicine is OeKolp forte? (Definition and Classification)

OeKolp forte is an Estrogen preparation primarily used to provide localized hormonal support, identified under the code G03CA03 (Estriol) within the category of Hormone Replacement Therapy (HRT) components. Estriol is a short-acting estrogen with selective action on the lower genitourinary tract, allowing the medicine to act directly on the vaginal and urogenital tissues. This formulation is characterized by its targeted effect on these specific areas. It is not a combined product; rather, it is a single-active-ingredient formulation targeting a specific local effect.


Composition, Form, and Origin: Understanding Estriol

The active ingredient in OeKolp forte is Estriol (E3), which is identified as a naturally occurring, or bio-identical, estrogen. The medication is administered as vaginal suppositories (also known as pessaries), making the vaginal route of administration key to its function. This physical dosage form is critical because the Estriol is dispersed within a solid, inert base that melts at body temperature, directly releasing the hormone to the target cells. This preparation is used for the treatment of estrogen deficiency symptoms in postmenopausal women to restore hormonal balance specifically in the local area of application, serving as a potent local treatment.


What is the General Purpose of This Estrogen Preparation?

The primary utility of OeKolp forte is to achieve replacement of endogenous estrogen in localized tissues, thereby supporting their health and function. By providing Estriol, the preparation helps counteract the effects of estrogen deficiency symptoms by exerting a localized estrogenic effect that restores and maintains the natural structure and vitality (trophism) of the vaginal and urogenital lining. This localized, targeted action is utilized for providing relief in scenarios where patients experience discomfort due to low estrogen levels in the vaginal area. The general purpose is therefore to support the biological integrity of these local tissues, improving the physical condition that is often impaired due to hormonal decline.

Regulatory References

  1. MedlinePlus Drug Information (Estrogen)
  2. UK's official Patient Information Leaflet (Estriol)
Advertisements

What side effects are possible with OeKolp forte?

Possible Side Effects and Safety Information

The safety profile of Estriol vaginal preparations is officially documented to include both expected localized reactions and the serious, systemic risks associated with the wider estrogen pharmacological class. The information below is based strictly on government regulatory documents, such as the Summary of Product Characteristics (SmPC).

Adverse Reactions and Frequency Classification

Adverse reactions are classified according to regulatory standards based on frequency. Local effects are most frequently observed, and are often described as transient or dose-related. Specific effects such as Vaginal bleeding or spotting have been formally classified as Rare in official documentation (occurring in 1/10,000 to 1/1,000 users). Other non-serious reactions noted in regulatory documents include local irritation, itching, pain at the application site, headache, and breast discomfort.

Systemic Safety Considerations (Class Effects)

Due to the potential for low systemic absorption, the product information includes mandated Systemic Estrogen Class Effects associated with Hormone Replacement Therapy (HRT). These are classified under system-organ groups that involve Vascular disorders, Neoplasms, and Hepatobiliary disorders.

Serious Adverse Reactions officially listed as class effects include Venous Thromboembolism (VTE) (such as Deep Vein Thrombosis and Pulmonary Embolism), Ischaemic Stroke, and Estrogen-dependent malignant neoplasms (including breast and endometrial cancer).

Safety Patterns and Restrictions

Regulatory texts note that the risk of VTE is more likely in the first year of using HRT. Furthermore, population-specific safety considerations apply: risk of endometrial cancer is noted for women with a uterus, and a risk of probable dementia is noted for those initiating HRT over the age of 65. The medicine must not be used in patients with a history of VTE, certain estrogen-dependent cancers, or acute liver disease, as per safety constraints documented in the regulatory label.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope: Officially Documented Manifestations

The regulatory profile for Estriol overdose, particularly in localized applications, focuses on signs of systemic estrogen excess. Overdose manifestations documented in official sources include symptoms such as nausea and vomiting, breast tenderness, fluid retention, headache, and potential vaginal bleeding (or spotting) [MedlinePlus]. The systems noted as being affected are the gastrointestinal, reproductive, central nervous, and fluid balance systems.

Overdose exposure, especially through accidental ingestion of multiple units, is generally considered to have a low risk of resulting in life-threatening outcomes, with official documents noting that serious symptoms are very unlikely [MedlinePlus].

Emergency Action Requirements

Action/Classification Official Regulatory Statement
Immediate Actions Required Seek medical help right away upon suspected overdose. Contact a certified Poison Help center or emergency services immediately for guidance [MedlinePlus].
Required Hospital Management Treatment is restricted to symptomatic and supportive treatment, as no specific antidote is known. Monitoring of vital signs may be required in a clinical setting [SmPC/FDA equivalent].
Urgent Medical Indicator Immediate medical investigation is mandated for any manifestation of undiagnosed abnormal genital bleeding resulting from estrogen excess [FDA/SmPC equivalent].

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by listing common, yet concerning, systemic symptoms of estrogen excess and noting that serious outcomes are very unlikely. This profile establishes the absolute requirement to seek medical help right away upon suspected exposure, particularly if excessive vaginal bleeding or severe systemic symptoms occur. The treatment approach is structured around providing symptomatic and supportive care while monitoring vital signs, as no specific regulatory-listed antidote is known.

Advertisements

Therapeutic Uses of OeKolp forte

Main Uses of OeKolp Forte

OeKolp forte is a hormone replacement therapy (HRT) designed for local application. It contains estriol, a naturally occurring female sex hormone. This medication is primarily used to manage symptoms and tissue changes associated with a deficiency in estrogen production, particularly during and after the menopause.

Treatment of Vaginal Atrophy

The primary application of this treatment is for vaginal atrophy, a condition where the vaginal walls become thinner, drier, and more fragile due to declining estrogen levels. By restoring estriol levels locally, the medication helps to:

  • Improve the thickness and elasticity of the vaginal mucosa.
  • Restore the natural pH balance of the vaginal environment.
  • Increase resistance to local infections and inflammation.

Relief of Menopausal Symptoms

In addition to structural changes, the medication is used to alleviate specific physical discomforts resulting from hormonal shifts, including:

  • Vaginal Dryness: Helping to restore natural lubrication.
  • Itching and Irritation: Reducing localized discomfort in the genital area.
  • Painful Intercourse: Addressing the underlying tissue thinning that can make physical intimacy uncomfortable.

Benefits for Urinary Health

Estrogen receptors are also present in the lower urinary tract. Consequently, the localized application of estriol can provide secondary benefits for urinary health in postmenopausal individuals. It may help in managing symptoms such as mild urinary urgency or discomfort during urination when these issues are linked to the thinning of the urethral lining.

Pre- and Post-Surgical Support

In certain clinical scenarios, this medication is used as a supportive measure for postmenopausal individuals undergoing vaginal surgery. It may be prescribed before a procedure to improve the health of the tissue for the surgeon, or after surgery to support the healing process of the vaginal lining.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use OeKolp forte?

This section outlines the officially documented population eligibility rules for OeKolp forte (Estriol vaginal suppositories) as defined by governmental regulatory authorities.

Approved Population

Use of this medicine is allowed only for postmenopausal women seeking local treatment for symptoms related to estrogen deficiency.

Absolute Contraindications

The medicine must not be used by patients who have or have had the following conditions, as they represent absolute contraindications:

  • Known, past, or suspected breast cancer or other estrogen-dependent malignant tumors.
  • Active or history of venous thromboembolism (VTE), arterial thromboembolic disease, or known thrombophilic disorders.
  • Undiagnosed genital bleeding or untreated endometrial hyperplasia.
  • Current or past severe liver disease where liver function has not returned to normal.
  • Known hypersensitivity to Estriol or any excipients.

Restricted Eligibility

Use is contraindicated during pregnancy and lactation.

Patients with certain pre-existing conditions, such as hypertension, diabetes mellitus, cardiac or renal dysfunction, or history of endometriosis, require close supervision during therapy.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for OeKolp forte (estriol) is primarily structured around the known potential for enzyme induction associated with estrogen metabolism. This profile is derived from the established pharmacological properties of estrogens, though its relevance is contextually constrained by the product's low systemic exposure.


Interaction-Related Restrictions

Official regulatory documents caution that certain medicinal products can affect the metabolism of estriol by acting as potent inducers of hepatic microsomal enzymes, such as Cytochrome P450 (CYP) and UDP-glucuronosyltransferases (UGTs). This induction process leads to an increased rate of estriol metabolism, which may result in a clinically significant decrease in systemic estriol exposure and subsequent reduction in the product's effectiveness.

The categories of interacting medicines that necessitate caution include specific anti-infectives, anticonvulsants, and certain herbal preparations. Specifically, potent enzyme-inducing agents such as barbiturates, carbamazepine, rifampicin, and preparations containing St John's wort (Hypericum perforatum) are listed as having the potential to cause this effect. The interaction constraints require that use with these agents be classified as use with caution and necessitates patient monitoring.


Contextual Constraints

A key constraint documented in the official profile is the vaginal route of administration. Due to the resulting minimal systemic absorption of the estriol, the clinical significance of these enzyme-inducing interactions is considered less likely or reduced compared to oral estrogen therapy. The overall interaction structure, therefore, requires a procedural constraint that patients must inform their healthcare provider about all concomitant medicines, including other steroids and specific Hepatitis C treatments (e.g., those containing ombitasvir/paritaprevir/ritonavir), to manage the risk of altered estriol effectiveness.

Advertisements

Mechanism of Action

OeKolp forte, which contains estriol (E3), functions as an agonist primarily targeting the nuclear estrogen receptors ( ERalpha and ERbeta). Estriol is classified as a relatively weak estrogen but exhibits binding affinity for both receptor subtypes, potentially demonstrating preferential interaction with ERbeta.

The mechanism proceeds via a classic genomic signaling pathway. Upon binding to estriol, the estrogen receptor undergoes a conformational change, forming a homodimer. This dimer complex then translocates to the cell nucleus. In the nucleus, the complex binds to specific DNA sequences known as Estrogen Response Elements (EREs), which are located near the promoter regions of target genes.

This binding event facilitates the recruitment of co-regulator proteins, ultimately modulating the transcription of estrogen-responsive genes. The downstream cascade involves the synthesis of specific proteins, leading to a generalized increase in the proliferation, differentiation, and maturation of epithelial cells in estrogen-sensitive tissues, such as the lower genitourinary tract. This cellular modulation results in increased tissue vascularity, elevated glycogen deposition, and enhanced connective tissue elasticity at the system level.

Advertisements

Dosage and Administration Information

The administration of OeKolp forte is governed by a specific, phased protocol with the objective of providing localized hormonal support via the vaginal route. The medication is available as 0.5 mg estriol vaginal suppositories.

Official Administration Schedule

The standard protocol follows a two-part dosing schedule for postmenopausal women:

Treatment Phase Dose Frequency Duration Principle
Initial Course 1 suppository (0.5 mg) Once daily Typically 3–4 weeks
Maintenance Course 1 suppository (0.5 mg) Twice weekly Shortest effective duration

Procedural and Contextual Instructions

The approved route is strictly intravaginal administration. The suppository is to be inserted deeply into the vagina. A key procedural instruction is to apply the medicine in the evening before bedtime to maximize local retention and absorption overnight.

If a dose is missed during the maintenance phase, it should be administered as soon as the omission is realized, unless it is close to the time of the next scheduled dose; in this case, the regular schedule is simply resumed, and the missed dose is skipped. Doubling the dose is not permitted. The treatment may also be prescribed specifically for use in the context of pre- and post-operative therapy for vaginal surgeries and for purposes of diagnostic assessment. The product is explicitly restricted from use in individuals under the age of 18.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for OeKolp forte

Evidence for Use in Vulvovaginal Atrophy (VVA) and Genitourinary Syndrome of Menopause (GSM)

Research has extensively explored the use of local estriol preparations, like OeKolp forte, in Randomized Controlled Trials (RCTs) and Systematic Reviews that included postmenopausal women. These studies monitored changes in physical signs of atrophy, such as epithelial thickness and vaginal pH levels, as well as patient-reported outcomes describing discomfort, including symptoms like vaginal dryness, burning, and pain during intercourse. Trials documented measurements of the objective tissue biomarkers and explored how patient-reported experiences were measured. Comparative evidence was observed in some studies against placebo or other local therapies.

Long-term effects are not well characterized by continuous, multi-year RCTs. Follow-up durations were limited in many primary studies, meaning the data available provides more insight into short-term changes. Comparative evidence with all currently available local treatments is limited.


Research on Related Lower Urinary Tract Symptoms

The research base for lower urinary symptoms associated with estrogen deficiency (e.g., urinary urgency) often relies on data gathered as secondary endpoints during trials. These studies examined the severity of urinary symptoms using patient-reported scores, and studies monitored the frequency of recurrent urinary tract infections (UTIs) in the observed populations. Research explored how patient-assessed urinary discomfort evolved over intermediate-term periods.

Evidence supporting long-term outcomes related to recurrent UTIs or complex urinary function is less consistent. The evidence base here is generally more limited than the data for the vaginal symptoms, as urinary outcomes were not always the primary focus.


Evidence Consistency and Remaining Uncertainties

The evidence quality varies across studies due to differences in design and comparison groups. The findings were mixed in some systematic summaries regarding the precise comparative evidence against every available alternative. The evidence contributes to understanding symptom patterns and describes group findings, not individual responses.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about OeKolp forte (FAQ)


Q: Does OeKolp forte contain hormones?

A: Yes, the active ingredient in the medication is estriol ( E3). This substance is officially classified as a naturally occurring estrogen hormone used to treat symptoms of local estrogen deficiency.


Q: Are there different strengths or dosages of OeKolp forte?

A: OeKolp forte is available as a single 0.5 mg estriol vaginal suppository strength. The dose remains constant, but the frequency of application is adjusted between the initial daily course and the less frequent maintenance course.


Q: Does the treatment require continuous use or is it short-term?

A: The treatment is structured in two distinct phases. It begins with an initial short-term daily course, which is then followed by a maintenance course that is applied less frequently (typically twice weekly) for the shortest effective duration.


Q: Is it possible to use OeKolp forte for too long?

A: Official documents emphasize that the treatment should be used for the shortest effective duration. Since the effects of prolonged, continuous use are not fully characterized by long-term studies, periodic re-evaluation by a healthcare provider is described as necessary.


Q: Can OeKolp forte be used by women who have had a hysterectomy?

A: Yes. This product is generally used by postmenopausal women. Official safety information indicates that the risk of endometrial cancer, a serious concern with estrogen treatment, is only relevant for women who still have a uterus.


Q: Can OeKolp forte be used after pelvic surgery?

A: Yes. The official prescribing information explicitly includes the use of this medication as a pre- and post-operative therapy specifically for vaginal surgeries.


Q: Can I use OeKolp forte if I have allergies to certain ingredients?

A: A known hypersensitivity (severe allergy) to the active ingredient, estriol, or to any of the inactive ingredients (excipients) in the suppository is an absolute contraindication. Official guidance indicates that reviewing the full list of ingredients with a pharmacist or healthcare professional is necessary.


Q: Can OeKolp forte make existing conditions worse?

A: The official product label lists certain pre-existing conditions that require close supervision when using this medication. Conditions such as hypertension (high blood pressure), diabetes, or heart/kidney dysfunction must be monitored closely because the medication can potentially impact them.


Q: Does the application method affect how well OeKolp forte works?

A: Yes. Official instructions specify that the suppository must be inserted deeply into the vagina and applied in the evening before bedtime. These instructions are procedural constraints intended to ensure maximum local retention and absorption of the medication.


Q: Are there specific instructions for what to do before or after using it?

A: Regulatory instructions primarily focus on the correct time (in the evening) and method (deep insertion) of application. For reasons of hygiene and safety, some guidance for similar products also includes washing hands before and after use.


Q: How soon after starting OeKolp forte can I expect side effects, if any?

A: The regulatory label notes that the risk of serious side effects, such as Venous Thromboembolism (VTE), is more likely to occur during the first year of use. The onset time for more common, non-serious local effects is not precisely defined but typically occurs early in the treatment phase.


Q: Are there any long-term effects of using this medication?

A: Regulatory texts caution about potential long-term risks associated with the estrogen class, such as an increased risk of blood clots, stroke, and certain cancers. However, official research summaries indicate that the long-term effects of this specific vaginal product are not fully characterized due to limitations in study follow-up duration.


Q: Can men use OeKolp forte for any condition?

A: No. The medication is explicitly licensed and approved only for use in postmenopausal women. It is not indicated or licensed for use by men for any condition.


Q: Does OeKolp forte interact with supplements or vitamins?

A: Yes, the official product information explicitly lists the herbal preparation St John's wort as a potent enzyme inducer that can decrease the medication’s effectiveness. Official product safety constraints indicate informing a healthcare provider about all supplements being taken is necessary.


Q: Can I use OeKolp forte if I am taking blood thinners?

A: The official product information for related estrogen treatments suggests that they may interact with certain blood thinners, such as warfarin. Due to the inherent systemic class risk of blood clots (VTE) associated with estrogens, official safety protocol advises that a healthcare provider be informed of all concomitant blood-thinning medications.


Q: Can OeKolp forte cause weight gain?

A: Weight gain has been noted in official reports as a possible side effect of related estrogens when used via the vaginal route. This effect is part of the established risk profile for this class of medication.


Q: Is it normal to have some discharge after using OeKolp forte?

A: Increased vaginal discharge, which may be thick or white, has been reported with the use of related vaginal estrogen products. This is often related to the suppository base dissolving. The presence of severe discharge or other concerning symptoms warrants consultation with a healthcare provider.


Q: Is OeKolp forte known to cause headaches or migraines?

A: Headache is listed in regulatory documents as a non-serious adverse reaction. While the product label does not explicitly mention migraine, the official information for related estrogen products includes migraine as a possible central nervous system reaction.


Q: Does OeKolp forte affect sex life or intercourse?

A: The medication's primary purpose is to relieve symptoms like pain during intercourse (dyspareunia). However, potential adverse reactions, such as vaginal irritation or discharge, have been reported and could temporarily affect intimacy.


Q: Can I stop using OeKolp forte once my symptoms are gone?

A: Official documents state that the maintenance dose should be used for the shortest effective duration necessary to control symptoms. Official guidance states that the decision regarding stopping or adjusting the therapy should be made under the guidance of a healthcare professional.


Q: What happens if I accidentally swallow OeKolp forte?

A: Accidental oral ingestion of related vaginal products has been associated with symptoms such as dizziness, nausea, vomiting, and stomach pain. Official instructions indicate that contacting a healthcare provider immediately is necessary if accidental ingestion occurs.


Q: Does OeKolp forte affect the results of lab tests?

A: Estrogen products are known to affect the results of various lab tests, including blood clotting measures and certain tests for thyroid function. Official procedural constraints include informing all healthcare providers and lab personnel that this medication is being used.


Q: Is OeKolp forte a steroid?

A: The active ingredient, estriol, is officially classified as an estrogen preparation. Estrogens are a class of naturally occurring hormones that belong to the larger family of steroid hormones.


Q: Why might a doctor prescribe OeKolp forte instead of an oral medication?

A: The medication is designed for local action, meaning it targets the vaginal tissues directly. This route of administration results in minimal systemic absorption, which is considered a key advantage over oral estrogen therapy for patients who only require localized hormonal support.


Q: Does alcohol consumption affect OeKolp forte?

A: Official guidance for related vaginal estrogen products advises limiting the consumption of alcohol. Drinking significant amounts of alcohol while using the medication may increase the risk of liver damage. Grapefruit juice should also be avoided as it may affect drug levels.

Advertisements

How should OeKolp forte be stored and disposed of?

Storage and Disposal of OeKolp forte Ovula 0.5 mg

The storage and disposal of OeKolp forte suppositories must strictly follow the conditions specified in the official regulatory labeling.


Storage Requirements

  • Temperature: The product must be stored at a temperature not exceeding 25, C.
  • Protection: To maintain stability, the suppositories must be kept in the original package to protect them from both light and moisture.
  • Child Safety: The medication must be securely kept out of the sight and reach of children.
  • Expiration: Do not use the medicine after the stated expiry date printed on the packaging.

Disposal Instructions

Official instructions prohibit the disposal of this medicine in wastewater or general household waste. Unused or expired medication must be handled according to local requirements. Patients should consult a pharmacist for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of OeKolp forte found in:

A-Z Index: